Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierAbCellera is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. We have built a platform for advancing antibody drug programs that we believe provides us with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities including multispecifics and antibody-drug conjugates.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Business segments
Q1 2026 · $8.3MThe company’s own SEC segment disclosure.
- Research Fees$8.1M98%
- Licensing And Royalty$191.0K2%
AbCellera Biologics Inc. (ABCL) reported revenue of $8.3M in Q1 2026 (quarter ended March 31, 2026), up 96% from the same quarter a year earlier. That came with net loss of $43M. For the full year FY2025, revenue was $75M (+161% year on year) and net income −$146M. Its largest product in 2026-Q1 was Research Fees at $8.1M, 98% of the disclosed total, just ahead of Licensing And Royalty at 2.3%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.